About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: To find a complete list of Publications, please see listing here.

 

Found 12 results
Filters: Author is Mendizabal, Adam  [Clear All Filters]
2021
R. Nakamura, Saber, W., Martens, M. J., Ramirez, A., Scott, B., Oran, B., Leifer, E., Tamari, R., Mishra, A., Maziarz, R. T., McGuirk, J., Westervelt, P., Vasu, S., Patnaik, M., Kamble, R., Forman, S. J., Sekeres, M. A., Appelbaum, F., Mendizabal, A., Logan, B., Horowitz, M., and Cutler, C., “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.”, Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2021.
2018
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
P. A. Carpenter, Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolaños-Meade, J., Sarantopoulos, S., Alousi, A. M., Abhyankar, S., Waller, E. K., Mendizabal, A., Zhu, J., O'Brien, K. A., Lazaryan, A., Wu, J., Nemecek, E. R., Pavletic, S. Z., Cutler, C. S., Horowitz, M. M., and Arora, M., “A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801.”, Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
2017
M. Eapen, Kurtzberg, J., Zhang, M. - J., Hattersely, G., Fei, M., Mendizabal, A., Chan, K. Wah, De Oliveira, S., Schultz, K. R., Wall, D., Horowitz, M. M., and Wagner, J. E., “Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.”, Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
2016
J. C. Alvarnas, Le Rademacher, J., Wang, Y., Little, R. F., Akpek, G., Ayala, E., Devine, S., Baiocchi, R., Lozanski, G., Kaplan, L., Noy, A., Popat, U., Hsu, J., Morris, L. E., Thompson, J., Horowitz, M. M., Mendizabal, A., Levine, A., Krishnan, A., Forman, S. J., Navarro, W. H., and Ambinder, R., “Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.”, Blood, vol. 128, no. 8, pp. 1050-8, 2016.
2015
A. C Howard, Fernandez-Vina, M. A., Appelbaum, F. R., Confer, D. L., Devine, S. M., Horowitz, M. M., Mendizabal, A., Laport, G. G., Pasquini, M. C., and Spellman, S. R., “Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2015.
2014
M. Eapen, O'Donnell, P., Brunstein, C. G., Wu, J., Barowski, K., Mendizabal, A., and Fuchs, E. J., “Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1485-92, 2014.
W. Saber, Le Rademacher, J., Sekeres, M., Logan, B., Lewis, M., Mendizabal, A., Leifer, E., Appelbaum, F. R., Horowitz, M. M., Nakamura, R., and Cutler, C. S., “Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1566-72, 2014.
2012
C. A. Keever-Taylor, Devine, S. M., Soiffer, R. J., Mendizabal, A., Carter, S., Pasquini, M. C., Hari, P. N., Stein, A., Lazarus, H. M., Linker, C., Goldstein, S. C., Stadtmauer, E. A., and O'Reilly, R. J., “Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.”, Biol Blood Marrow Transplant, vol. 18, no. 5, pp. 690-7, 2012.
M. C. Pasquini, Devine, S., Mendizabal, A., Baden, L. R., Wingard, J. R., Lazarus, H. M., Appelbaum, F. R., Keever-Taylor, C. A., Horowitz, M. M., Carter, S., O'Reilly, R. J., and Soiffer, R. J., “Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl”, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.